Epidural Dexmedetomidine for Cesarean Delivery

Guideline Recommendations

The American College of Obstetricians and Gynecologists (ACOG) guideline (2026) lists epidural dexmedetomidine as a valid option for anesthesia and analgesia in cesarean delivery, with intravenous, epidural, and intrathecal routes all approved. 1
The American Society of Anesthesiologists (ASA) 2024 statement recommends epidural dexmedetomidine as a rescue adjunct for intra‑operative visceral pain caused by peritoneal traction. 3
The ASA also notes that about 15 % of cesarean sections experience intra‑operative pain despite adequate neuraxial anesthesia, supporting the need for rescue strategies. 3
For patients at high risk of severe acute postoperative pain, the ASA recommends adding neuraxial α‑2‑adrenergic agonists (epidural dexmedetomidine or intrathecal clonidine 30–50 µg) to the anesthetic regimen. 3
The 2026 guideline panel classifies dexmedetomidine as the highest‑ranked pharmacologic agent for preventing intra‑ and postoperative shivering during cesarean delivery, based on a meta‑analysis of 20 RCTs (1,983 participants) providing Level I evidence. 5

Functional epidural catheter already in place for labor analgesia that will be used for the cesarean qualifies the patient for epidural dexmedetomidine use. 1
Risk factors that justify considering epidural dexmedetomidine include:
Anticipated significant intra‑operative visceral pain (e.g., complex or repeat cesarean, high maternal anxiety) is an indication for epidural dexmedetomidine. 3
When intra‑operative pain persists despite adequate neuraxial anesthesia, dexmedetomidine may be employed as a rescue strategy. 3
Patients who develop significant shivering during cesarean delivery are candidates for dexmedetomidine, per both the ASA and the guideline panel. [3][5]

Dexmedetomidine is a highly selective α‑2 adrenergic agonist (α2:α1 ratio ≈ 1620:1) providing analgesia, sedation, anxiolysis, and anti‑shivering effects. (ASA). 3
Analgesia is mediated through activation of spinal and supraspinal α‑2 receptors, reducing visceral nociceptive transmission. (ASA). 3
Sedation occurs via α‑2A receptors in the locus coeruleus and does not produce clinically important respiratory depression. (ASA). 3
Low‑dose intravenous dexmedetomidine attenuates shivering induced by neuraxial anesthesia in cesarean patients. (ASA). 3

Visceral pain reduction: Epidural dexmedetomidine lessens peritoneal traction‑related visceral pain and uterine‑contraction pain compared with morphine alone. (ASA). 3
Improved sedation: Provides deeper intra‑operative and early post‑operative sedation without increasing morphine‑related side effects. (ASA). 3
Shivering prevention: Demonstrated to lower the incidence of intra‑ and postoperative shivering, supporting its ranking as the preferred anti‑shivering agent. (Guideline Panel, Level I). 5

Regulatory status: The U.S. Food and Drug Administration (FDA) approved dexmedetomidine in 1999 for ICU sedation and in 2008 for procedural sedation in non‑intubated patients; epidural or intrathecal use is off‑label. 3
Cardiovascular effects: Dexmedetomidine may modestly lower systolic and diastolic blood pressure and heart rate; routine co‑administration of anticholinergics is discouraged due to risk of tachycardia, hypertension, and arrhythmias. (ASA). 3
Neonatal safety: No significant differences in 1‑ and 5‑minute Apgar scores or umbilical cord blood gases have been observed. (ASA). 3

A recommended multimodal protocol includes:
Opioids should be reserved strictly for breakthrough or rescue pain; routine scheduled opioid administration is not recommended. (Guideline Panel). 6